Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748349 | 0.92 | F2R (0.54) | F2RRAB9ANPC1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6750474 | 0.90 | F2R (0.53) | F2RRAB9ANPC1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6748346 | 0.84 | F2R (0.55) | F2RRAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL5484953 | 0.74 | F2R (0.42) | F2R | |
| SCHEMBL1731654 | 0.74 | F2R (0.67) | F2R | |
| SCHEMBL6746421 | 0.73 | F2R (0.54) | F2RRAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL1730675 | 0.72 | F2R (0.59) | F2R | |
| SCHEMBL6364086 | 0.72 | F2R (0.66) | F2R | |
| SCHEMBL1729433 | 0.72 | F2R (0.48) | F2R | |
| Bromide SCHEMBL2346025 | 0.71 | F2R (0.98) | F2RRAB9ANPC1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | H1-2, H1-0, H1-3 | F2R 4027/4885RAB9A 1696/4885NPC1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.